This Medudy course is a video tutorial for physicians on the topic of “EHA Congress Update.”
In this video, Dr. Jörg Chromik, senior physician and director of the Hematology Outpatient Clinic at Frankfurt University Hospital, discusses three selected study highlights on PNH from the 2026 EHA Congress.
First, real-world data from the COMPLETE study will be presented; this is an ongoing Phase 4 observational study examining treatment with the C3 inhibitor pegcetacoplan in clinical practice. In the second part, initial results from a controlled Phase 3 trial will be presented, comparing the factor B inhibitor HSK39297 with eculizumab monotherapy in PNH patients who have not previously received complement inhibitors. Finally, a molecular analysis of clonal architecture and dynamics in aplastic anemia and PNH will be presented, which, based on somatic phylogenies, allows conclusions to be drawn about the temporal course of clonal evolution.
Note: All “speakers” appearing in the Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. The video content was created and reviewed by the editorial team with the aid of AI, based on high-quality scientific sources, and has been approved by the speakers.
This course was created with the kind support of Sobi.
By the end of this course, you will know:
- The latest real-world data from the COMPLETE study on pegcetacoplan for PNH
- Results of the comparison of HSK39297 and eculizumab in PNH patients who have not previously received complement inhibitors
- Molecular insights into the clonal architecture and dynamics of aplastic anemia and PNH
- Placing these EHA 2026 conference highlights in the clinical context of PNH treatment
